AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 211 min read$NUVB

Hattersley Gary sold $709K of NUVB

Hattersley Gary (CHIEF SCIENTIFIC OFFICER) sold 100,000 shares of Nuvation Bio Inc. (NUVB) at $7.09 ($0.71M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hattersley Gary
Published Aug 21, 2026, 8:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NUVB
Bearish
medium confidence
Mentioned
$NUVB
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NUVBBearishLow
01

Why it matters

The CSO's complete exit could be interpreted as a negative signal, but the 10b5‑1 plan suggests pre‑planned execution.

02

Market read

Primary insider sale with modest size; limited trading impact but worth noting for risk‑aware investors.

03

What to watch

Potential upcoming clinical milestones that could offset negative perception.

Relevance 4/10Novelty 4/10Timing: post‑filing 2026‑08‑21

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$NUVBBearishMedium confidence
Context

Chief Scientific Officer sold 100,000 shares for $709,240 via a 10b5-1 plan, reducing his stake to zero.

Expected impact

Modest short‑term downside pressure

Evidence & confidence

The sale size is modest relative to market cap, but the CSO exiting completely could be viewed negatively by investors.

Market effects

Sector

Limited impact on biotech sector; similar insider sales are common.

Regional

No regional effect beyond the company's own stock.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The sale may be purely portfolio rebalancing under a pre‑arranged plan, not a confidence signal.

Key entities

  • company
    Nuvation Bio Inc.

    Biotech firm developing RNA‑based therapeutics.

  • person
    Hattersley Gary

    Chief Scientific Officer of Nuvation Bio.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NUVB insider trading history →

Related articles

OCT 2
$NUVBHigh

Citigroup Turns to 2 Promising Biotech Stocks

Citigroup initiated coverage on Nuvation Bio (NUVB) and Jazz Pharmaceuticals (JAZZ) with Buy ratings. NUVB received a $12 price target, citing strong sales of Ibtrozi and potential of safusidenib. JAZZ was given a $320 target, highlighting Ziihera's growth potential. Both stocks are seen as covered call opportunities.

pro.thestreet.com2 min
SEP 18
$RAREMed

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

rttnews.com3 min
SEP 17
$NUVBHighAI 8/10

Nuvation Bio Wins FDA Nod For Updated IBTROZI Label Showing 50-Month DOR In ROS1+ Lung Cancer

Nuvation Bio (NUVB) announced FDA approval for its drug IBTROZI, updating the label to include long-term efficacy data showing a median duration of response of 49.7 months in treatment-naïve ROS1+ NSCLC patients. The approval is based on data from the TRUST-I study, with no changes to the safety profile. NUVB stock closed at $5.78, up 3.07% in pre-market trading.

rttnews.com2 min
SEP 17
$NUVBHighAI 8/10

Nuvation Bio stock gains on FDA label update for IBTROZI

Nuvation Bio Inc (NUVB) shares rose 5.5% after the FDA approved a label update for IBTROZI, adding 49.7-month median duration of response data. The update reflects longer-term data from the TRUST-I study, with no new safety concerns. IBTROZI is approved for treating ROS1-positive non-small cell lung cancer. The FDA approval came ahead of schedule, and the drug is also approved in Japan and China.

investing.com2 min
SEP 17
$NUVBHighAI 9/10

Nuvation Bio announces FDA approval of sNDA for Ibtrozi

Nuvation Bio (NUVB) received FDA approval for its supplemental New Drug Application for Ibtrozi, a ROS1 inhibitor. The updated label includes a median duration of response of 49.7 months in TKI-naive patients, with no changes to safety information. The approval reflects sustained clinical benefit for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer.

tipranks.com1 min